At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Abataceptdrug
Likely dose
Abatacept 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Openlabel, Phase II Trial of Abatacept (Orencia) in the Treatment of Refractory Non-infectious Uveitis.
In Brief
A Phase 2 clinical trial evaluating Abatacept for Uveitis. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of abatacept in the treatment of uveitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartJan 2012
Primary CompletionJun 2017
TodayJul 2026
First PostedJan 20, 2011
Enrollment StartJan 1, 2012
Primary CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 15.5 years ago
Interventions
Abataceptdrug
Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg. Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years.